AXSOME THERAPEUTICS, INC. Additional Paid in Capital, Common Stock
AXSOME THERAPEUTICS, INC. (AXSM) had Additional Paid in Capital, Common Stock of $1.51 billion as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-10
- 2026-06-30: Additional Paid in Capital, Common Stock $1.51B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.43B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.39B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.35B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $1.51B 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $1.43B 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $1.39B 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $1.35B 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $1.30B 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $1.24B 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $1.18B 10-K · filed 2026-02-23 | |
| 2024-09-30 | $1.14B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $1.09B 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $1.05B 10-Q · filed 2024-05-06 | |
| 2023-12-31 | $1.03B 10-K · filed 2025-02-18 | |
| 2023-09-30 | $1.01B 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $953.52M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $719.36M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $705.88M 10-K · filed 2024-02-23 | $705.88M 10-K · filed 2023-02-28 |
| 2022-09-30 | $692.45M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $505.47M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $463.53M 10-Q · filed 2022-05-02 | |
| 2021-12-31 | $424.83M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $417.94M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $411.77M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $404.35M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $392.59M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $354.61M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |